When the National Academies of Science, Engineering and Medicine released its FDA-funded report on cBHT last summer, FDA issued a public statement saying it would base its next steps on compounded hormones on that report, a statement widely interpreted to mean FDA will act to restrict compounded hormone therapy. These are therapies that many patients rely on for their quality of life. The NASEM report has a number of apparent flaws that negate its credibility that are documented in a new white paper from the Berkeley Research Group, commissioned by the Pharmacy Compounding Foundation. Here’s a summary of that white paper. In addition, the Alliance for Pharmacy Compounding is mounting a campaign to help patients share their compounded hormone success stories with members of Congress. Learn more about the media campaign – and contribute to the effort – here. The landing page for patients to share those testimonials with members of Congress can be found here.
NCPA
